Hypoxia Aggravates Inactivity-Related Muscle Wasting
نویسندگان
چکیده
منابع مشابه
Quadriceps wasting and physical inactivity in patients with COPD.
Quadriceps weakness is an important complication of advanced chronic obstructive pulmonary disease (COPD) but few data exist concerning muscle bulk in early disease. We hypothesised that quadriceps bulk, measured by ultrasound rectus femoris cross-sectional area (USRF(CSA)), would be reduced in mild, as well as advanced, COPD compared with controls, and would correlate with physical activity. 1...
متن کاملMuscle Wasting and IL - 6
Muscle wasting is a common feature of systemic inflammation and malignant diseases. The primary cause is accelerated proteolysis. Protein degradation was found to be accelerated by IL-6 with activation of intracellular proteases in C2C12 myotubes. IL-6 transgenic mice displayed extensive muscle wasting together with an increase of proteolytic pathways. The increase in activities and mRNA levels...
متن کاملHuman skeletal muscle wasting in hypoxia: a matter of hypoxic dose?
TO THE EDITOR: The authors of the Viewpoint (2) propose that a cut-off point for initiation of hypoxia-induced muscle wasting is ~5,000 km·h. Although they employ a valuable new metric, incorporating elevation and total exposure time, we previously suggested that it might be better to quantify the hypoxic stimuli by using “saturation hours” (4). This is particularly important given that both (d...
متن کاملSkeletal muscle loss: cachexia, sarcopenia, and inactivity.
Loss of skeletal muscle mass occurs during aging (sarcopenia), disease (cachexia), or inactivity (atrophy). This article contrasts and compares the metabolic causes of loss of muscle resulting from these conditions. An understanding of the underlying causes of muscle loss is critical for the development of strategies and therapies to preserve muscle mass and function. Loss of skeletal muscle pr...
متن کاملPyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1α.
Pulmonary arterial hypertension (PAH) is a refractory disease characterized by uncontrolled vascular remodeling and elevated pulmonary arterial pressure. Although synthetic inhibitors of some tyrosine kinases have been used to treat PAH, their therapeutic efficacies and safeties remain controversial. Thus, the establishment of novel therapeutic targets based on the molecular pathogenesis underl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Physiology
سال: 2018
ISSN: 1664-042X
DOI: 10.3389/fphys.2018.00494